ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. Journal of clinical oncology. United States: American Society of Clinical Oncology, 2007, vol. 25, No 25, p. 3892-3901. ISSN 0732-183X. |
Other formats:
BibTeX
LaTeX
RIS
@article{837837, author = {Orlowski, RZ. and Nagler, A. and Sonneveld, P. and Bladé, J. and Hájek, Roman}, article_location = {United States}, article_number = {25}, keywords = {multiple myeloma; bortezomib;doxorubicin}, language = {eng}, issn = {0732-183X}, journal = {Journal of clinical oncology}, title = {Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.}, volume = {25}, year = {2007} }
TY - JOUR ID - 837837 AU - Orlowski, RZ. - Nagler, A. - Sonneveld, P. - Bladé, J. - Hájek, Roman PY - 2007 TI - Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. JF - Journal of clinical oncology VL - 25 IS - 25 SP - 3892-3901 EP - 3892-3901 PB - American Society of Clinical Oncology SN - 0732183X KW - multiple myeloma KW - bortezomib;doxorubicin N2 - This phase III international study compared the efficacy and safety of a combination of pegylated liposomal doxorubicin (PLD) plus bortezomib with bortezomib monotherapy in patients with relapsed or refractory multiple myeloma. PLD with bortezomib is superior to bortezomib monotherapy for the treatment of patients with relapsed or refractory multiple myeloma. The combination therapy is associated with a higher incidence of grade 3/4 myelosuppression, constitutional symptoms, and GI and dermatologic toxicities. ER -
ORLOWSKI, RZ., A. NAGLER, P. SONNEVELD, J. BLADÉ and Roman HÁJEK. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. \textit{Journal of clinical oncology}. United States: American Society of Clinical Oncology, 2007, vol.~25, No~25, p.~3892-3901. ISSN~0732-183X.
|